Clinical trial NCT00555061: Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
Official title: An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Skin Infections, Bacterial
Keywords: SID
impetigo
pharmacokinetics
Retapamulin ointment, 1%
Skin abnormalities
Dermatoses
pediatric
infection
SITL
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2007-11-07
Enrollment: 60
Sex: ALL
Minimum age (years): 2
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).


Eligibility criteria: Inclusion criteria:

* Subject Age: The subject is ≥2 months to ≤24 months of age at study entry
* Subject Diagnosis: The subject has a diagnosis of secondarily-infected traumatic lesion (SITL), secondarily-infected dermatoses (SID), or primary impetigo (bullous or non-bullous) that is suitable for treatment with topical antibacterial therapy:

The subject has a small laceration, sutured wound or abrasion, which has a secondary bacterial infection. The infected portion of the laceration or sutured wound should not exceed 10cm in length with surrounding erythema not extending more than 2cm from the edge of the wound. Abrasions should not exceed 2% of the total body surface area with surrounding erythema not extending more than 2cm from the edge of the abrasion.

The subject has a diagnosis of inflammatory skin disease (i.e., dermatosis), such as atopic dermatitis or contact dermatitis, which has a secondary bacterial infection. The infected portion of the lesion(s) should not exceed 2% of the total body surface area.

Impetigo: The subject has a lesion or group of £10 discrete localized lesions on otherwise healthy skin, characterized by red spots or blisters without crusts which later progress to lesions which ooze and form yellow or honey-colored crusts surrounded by an erythematous margin.

* Subject SIRS Score: The subject has a total SIRS score of at least 8 (Appendix 1 Skin Infection Rating Scale)
* Protocol Compliance: The parent/legal guardian is willing to comply with the protocol
* Informed Consent: The parent/legal guardian has given written informed, dated consent for the subject to participate in the study
* French Subjects: In France, a subject will be eligible for inclusion in this study if either affiliated to or a beneficiary of a social security category

Exclusion criteria:

* The subject has demonstrated a previous hypersensitivity reaction to pleuromutilin or any component of the ointment (refer to the Investigator Brochure for composition of Retapamulin ointment, 1%)
* The subject was considered to be premature at birth (\<37 weeks gestation)
* The subject has a secondarily-infected animal/human bite, or a puncture wound
* The subject has an abscess
* The subject has a chronic ulcerative lesion that is unlikely to have Staphylococcus aureus or Streptococcus pyogenes as the causative agent
* The subject has systemic signs and symptoms of infection (such as fever; defined as a temperature equivalent to a rectal temperature greater than 101°F or 38.3°C)
* The subject has a bacterial skin infection which, due to area, depth or severity, in the opinion of the investigator, cannot be appropriately treated by a topical antibiotic
* The subject has more than one type of infected lesion as defined in the protocol
* The subject requires surgical intervention for treatment of the infection prior to enrollment in the study, or is likely to require such intervention during the course of the study
* The subject has applied any topical therapeutic agent (including glucocorticoid steroids, antibacterials or antifungals) directly to the infected wound/lesion, within 24 hours prior to study entry
* The subject has received one or more days of treatment with a systemic antibacterial within 72 hours of study entry
* The subject is receiving systemic corticosteroids at a dose of \>0.125mg/kg per day of prednisone (or the equivalent)
* The subject has a known, pre-existing, serious underlying disease that could be imminently life-threatening
* The subject has participated in any study using an investigational drug during the previous 30 days prior to entering the study
* The subject has been previously enrolled in this study or in any other study involving Retapamulin

Primary outcomes:
measure: Number of Participants With Measurable Plasma Concentrations, by Age Group
timeFrame: Days 3 to 4; 4 to 8 hours post-dose of the first dose of the day
Secondary outcomes:
measure: Number of Participants With Clinical Success at Follow-up, by Type of Skin Infection and by Age
timeFrame: Follow-up, Days 12 to 16
measure: Bacteriological Success Rate at Follow-up, by Baseline Pathogen
timeFrame: Follow-up, Days 12 to 16
measure: Number of Participants by Age With Therapeutic Response of Success
timeFrame: Follow-up, Days 12 to 16
Other outcomes:
Locations:
city: Tuscaloosa
country: United States
facility: GSK Investigational Site
state: Alabama
city: Bentonville
country: United States
facility: GSK Investigational Site
state: Arkansas
city: Orange
country: United States
facility: GSK Investigational Site
state: California
city: Woburn
country: United States
facility: GSK Investigational Site
state: Massachusetts
city: Cleveland
country: United States
facility: GSK Investigational Site
state: Ohio
city: Houston
country: United States
facility: GSK Investigational Site
state: Texas
city: Ciudad Autonoma de Buenos Aires
country: Argentina
facility: GSK Investigational Site
state: Buenos Aires
city: Ciudad Autonoma de Buenos Aires
country: Argentina
facility: GSK Investigational Site
state: Buenos Aires
city: Santiago
country: Chile
facility: GSK Investigational Site
state: Región Metro De Santiago
city: San Jose
country: Costa Rica
facility: GSK Investigational Site
city: Noerdlingen
country: Germany
facility: GSK Investigational Site
state: Bayern
city: Bochum
country: Germany
facility: GSK Investigational Site
state: Nordrhein-Westfalen
city: Erkrath
country: Germany
facility: GSK Investigational Site
state: Nordrhein-Westfalen
city: Goch
country: Germany
facility: GSK Investigational Site
state: Nordrhein-Westfalen
city: Kleve-Materborn
country: Germany
facility: GSK Investigational Site
state: Nordrhein-Westfalen
city: Mexico
country: Mexico
facility: GSK Investigational Site
city: Alphen A/d Rijn
country: Netherlands
facility: GSK Investigational Site
city: Losser
country: Netherlands
facility: GSK Investigational Site
city: Roelofarendsveen
country: Netherlands
facility: GSK Investigational Site
city: Rotterdam
country: Netherlands
facility: GSK Investigational Site
city: Soerendonk
country: Netherlands
facility: GSK Investigational Site
city: Woerden
country: Netherlands
facility: GSK Investigational Site
city: Benoni
country: South Africa
facility: GSK Investigational Site
city: Newtown
country: South Africa
facility: GSK Investigational Site
city: Taipei
country: Taiwan
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: